The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
about
Clinical significance of human papillomavirus genotypingClinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) studyFrom Human Papillomavirus (HPV) Detection to Cervical Cancer Prevention in Clinical Practice.Expressed prostate secretions in the study of human papillomavirus epidemiology in the maleEvaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimensPatterns of human papillomavirus types in multiple infections: an analysis in women and men of the high throughput human papillomavirus monitoring study.Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination.Comparison of Hybribio GenoArray and Roche human papillomavirus (HPV) linear array for HPV genotyping in anal swab samplesHuman papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women.Human papillomavirus infection is rare in nonmalignant tonsil tissue in the UK: implications for tonsil cancer precursor lesions.Rates and determinants of oral human papillomavirus infection in young menComparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.HPV Genotyping of Modified General Primer-Amplicons Is More Analytically Sensitive and Specific by Sequencing than by Hybridization.Human Papillomavirus (HPV) Genotyping: Automation and Application in Routine Laboratory Testing.HPV Population Profiling in Healthy Men by Next-Generation Deep Sequencing Coupled with HPV-QUEST.Characterization of Intra-Type Variants of Oncogenic Human Papillomaviruses by Next-Generation Deep Sequencing of the E6/E7 RegionEpidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination.Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency StudyComparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping.Human papillomavirus infections in nonsexually active perinatally HIV infected childrenHuman papillomavirus vaccines: key factors in planning cost-effective vaccination programs.Long-term HPV type-specific risks for ASCUS and LSIL: a 14-year follow-up of a randomized primary HPV screening trial.The prevalence of HPV infections in HPV-vaccinated women from the general population.Prevalence of tonsillar human papillomavirus infections in Denmark.Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial.Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
P2860
Q26771981-C80334EC-3DA6-4C7C-A9E8-D8B64FA0875CQ30651813-8A67FBF2-08EB-4BCC-A234-9B9D11B7132EQ34774870-E8904A37-4342-4B78-AC47-468931A0E4BEQ34782761-A87DF027-91C5-45D5-BE4B-4E28C6245BC6Q34964786-85525E3A-D089-4A21-8BE7-92CE031376BDQ34971664-9BAF440D-2984-4697-AEA0-4A6AA417629DQ34974475-B4A911FC-08D6-40F6-A576-B3A4D1FD7CB9Q34983076-5FDD3CEB-9240-49FA-8221-7EC9B1EA590DQ35050431-D0765A6E-1F14-4841-8887-4A1C15821728Q35145756-2151DFDC-9BD2-4071-8ED1-E8249A50BCFAQ35221457-F02E8282-EF3F-42DB-9E26-B6520906AD89Q35342179-04B8A5E2-D763-4778-9A9E-703BBF990C1CQ36238070-C2FA2AAD-4CCD-4FAA-89E6-DE8005207D24Q36466049-546BFD2F-B84A-4CA8-9B31-B958EB6BBD30Q36645480-6C3FD699-4251-4FDD-B88D-842B08718DF5Q36735676-DFED2424-2784-4779-BC4A-FB810E4D2414Q37078556-1AE7C6C9-B53C-4626-920A-A302FBA73178Q37496183-8EAF9374-4D80-4937-BF4C-ABFD6A9B2F8BQ37503427-FBC0AE64-B1DF-4C8D-9269-673FE870BD4FQ37546177-089FBD40-8B01-45F9-BA0A-BEE6453D1ADAQ37546224-7E95DFC9-8953-4DE3-80F7-3626C014A7DAQ37587903-08A5BD0F-9482-4021-B5F1-50F70EB30FB9Q38255277-76CD4C7E-B550-4B25-BBE8-AA80FF5B6918Q39189708-7F6878A3-3BD4-44D5-ADBD-832C67E9146EQ40291505-314277CC-0E8F-4648-95B4-CACD919E7190Q42200672-732F47B6-7575-40C9-AFC9-AC352C815B86Q42204957-00017B00-DF55-4342-A8C1-FACA52B16AC8Q49165143-36527F05-3617-4DBB-BE62-42F7BA117123
P2860
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
@ast
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
@en
type
label
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
@ast
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
@en
prefLabel
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
@ast
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
@en
P2093
P2860
P356
P1476
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.
@en
P2093
Carina Eklund
Keng-Ling Wallin
Ola Forslund
Tiequn Zhou
WHO Human Papillomavirus Laboratory Network
P2860
P304
P356
10.1128/JCM.00840-12
P407
P577
2012-04-25T00:00:00Z